title: Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival.
abstract: Donor leukocytes administered at the time of transplantation may prolong organ allograft survival. This study examined the effectiveness of donor leukocyte injection combined with immunosuppression for limb transplantation across the strong histocompatibility barrier of a Brown Norway donor to a Lewis recipient. Eight animals received 6 x 10(7) donor leukocytes injected on the day of transplantation. From day 1, FK506 (2 mg/kg/d), mycophenolate mofetil (MMF) (15 mg/kg/d), and prednisone (0.5 mg/kg/d) were administered for 2 weeks. After week 2, prednisone and MMF were both tapered by 20% of the initial dosage per week. After week 7, the animals received only FK506 (2 mg/kg/d). From week 8, FK506 was tapered to the maintenance dose of 0.8 mg/kg/d at week 10 and was stopped on week 24. A control group of 8 animals underwent identical treatment except that the leukocyte injection was omitted. Rejection was observed in both groups during FK506 monotherapy; however, the onset of early rejection episodes was significantly later, the period for reversal of the first rejection was significantly shorter, and the dosage of FK506 at the time of rejection was significantly lower among leukocyte-treated recipients. After completion of immunosuppression, survival was modestly prolonged in the leukocyte-treated group. One animal is surviving without immunosuppression on day 234. This trial of donor leukocyte injection combined with immunosuppression in limb transplantation showed a modest, but significant, improvement in outcome.
authors.affiliation: Department of Orthopedics, Kobe Rosai Hospital, 4-1-23 Kagoike-dori, Chuo-ku, Kobe 651-0053, Japan. takakokatie@kobeh.rofuku.go.jp
authors.forename: T
authors.initials: T
authors.lastname: Kanatani
authors.forename: M
authors.initials: M
authors.lastname: Lanzetta
authors.forename: E
authors.initials: E
authors.lastname: Owen
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: H
authors.initials: H
authors.lastname: Fujioka
authors.forename: M
authors.initials: M
authors.lastname: Kurosaka
authors.forename: G W
authors.initials: GW
authors.lastname: McCaughan
authors.forename: G A
authors.initials: GA
authors.lastname: Bishop
mesh_terms: D000818:Animals; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006614:Hindlimb / Q000637:transplantation*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017708:Leukocyte Transfusion; D023421:Models, Animal; D011241:Prednisone / Q000627:therapeutic use; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology*
chemical_list: D007166:Immunosuppressive Agents; D011241:Prednisone; D016559:Tacrolimus